Tactile Systems Technology shows strong growth, cash conversion, and momentum, but a thin upside margin that failed the engine's asymmetry gate, an overbought technical read, leverage, and insider selling lead the engine to recommend reducing the position.
Thesis pillars
- Thin Upside Failed Asymmetry↑Improving
- Strong Growth And Cash Conversion→Stable
- Overbought Momentum Above Max Pain↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Tactile Systems Technology, Inc (TCMD) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $22.62, but acceptable to hold if already in. Reasons: Concentration risk — Product: lymphedema products (84.0%); Concentration risk — Supplier: single-source component suppliers.
Tactile Systems Technology (Tactile Medical) is a medical device company that develops at-home therapies for underserved chronic conditions, primarily lymphedema and chronic venous insufficiency (Flexitouch Plus, Entre Plus, Nimbl) and chronic respiratory disease (AffloVest).... Read more
Hold if already holding. Not a fresh buy at $22.62, but acceptable to hold if already in. Reasons: Concentration risk — Product: lymphedema products (84.0%); Concentration risk — Supplier: single-source component suppliers. Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 20d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Tactile Systems Technology, Inc
About Tactile Systems Technology, Inc
Tactile Systems Technology generated $329.5 million in revenue in 2025, up 12% from 2024, with lymphedema devices — Flexitouch Plus, Entre Plus, and Nimbl — contributing $278.4 million, or 84% of revenue, and its AffloVest respiratory device contributing $51.1 million, or 16%. The company estimates it is in-network with payers covering more than 278 million lives in the U.S. and served over 84,000 patients with its compression therapy devices in 2025 alone, cumulatively treating more than 635,000 patients since launch. Net income reached $19.1 million for the year.
Tactile earns revenue through a direct-to-patient and -provider model for its lymphedema portfolio, managing insurance claims and delivering devices directly to patients, while its AffloVest respiratory line is sold through third-party durable medical equipment providers who handle reimbursement documentation, patient training, and support. The company relies on third-party, single-source suppliers for some components and materials across its Flexitouch Plus, Entre Plus, Nimbl, and AffloVest systems, exposing it to disruption if any one supplier cancels an arrangement or fails to deliver. Reimbursement is central to the business model: Medicare's National Coverage Determination for pneumatic compression devices will begin requiring prior authorization for Tactile's product codes starting April 13, 2026, following the November 2024 retirement of the prior Local Coverage Determination. Tactile's commercial infrastructure includes a payer-relations team, a reimbursement-operations team handling prior authorizations and appeals, and a clinical team led by a Chief Medical Officer that develops evidence supporting coverage decisions.
Show full overview
Two structural dependencies sit beneath Tactile's growth story. First, the company's own single-source suppliers for select components across all four of its device platforms mean a canceled arrangement or supplier disruption could delay shipments faster than Tactile could qualify a replacement, since new suppliers may require additional regulatory approval. Second, revenue is heavily weighted toward one clinical franchise — lymphedema products were 84% of 2025 revenue — and AffloVest, the offsetting respiratory line, is itself dependent on third-party DME providers for essentially all sales, reimbursement, and patient training; the 10-K cites a 2023 episode in which a single large DME provider's slowed placements measurably dented airway-clearance revenue. A Medicare prior-authorization requirement for pneumatic compression devices taking effect April 13, 2026 adds a near-term, dated regulatory test of how much friction the reimbursement process can absorb before it affects shipments.
See also: Healthcare · Medical Devices
From Tactile Systems Technology, Inc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-13Recent Developments — Tactile Systems Technology, Inc
Latest news
- NEWS At US$30.14, Is It Time To Put Tactile Systems Technology, Inc. (NASDAQ:TCMD) On Your Watch List? - Sahm — Sahm neutral
- NEWS Earnings Preview: TCMD to Report Financial Results Post-market on August 10 - news.futunn.com — news.futunn.com neutral
- NEWS Segall Bryant & Hamill LLC Acquires New Holdings in Tactile Systems Technology, Inc. $TCMD - MarketBeat — MarketBeat neutral
- NEWS Janus Henderson Group PLC Purchases 127,942 Shares of Tactile Systems Technology, Inc. $TCMD - MarketBeat — MarketBeat neutral
- NEWS Earnings Preview: TCMD to Report Financial Results Post-market on August 10 - 富途牛牛 — 富途牛牛 neutral
Generated 2026-10-13T11:32:15Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductlymphedema products84%10-K Item 1A: 'Our lymphedema products accounted for 84% and 89% of our revenue for the years ended December 31, 2025 and 2024, respectively.'
- HIGHSuppliersingle-source component suppliers10-K Item 1A: 'We utilize third-party, single-source suppliers for some components and materials used in our products, and the loss of any of these suppliers could have an adverse impact on our business.'
- HIGHcounterpartyDME providers (AffloVest distribution)10-K Item 1A: 'because we fully rely on DME providers related to sales of our AffloVest product, any disruption affecting those DMEs could adversely impact our results'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $22.62, but acceptable to hold if already in. Reasons: Concentration risk — Product: lymphedema products (84.0%); Concentration risk — Supplier: single-source component suppliers. Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Target $33.15 (+46.6%), stop $21.42 (−5.6%), A.R:R 8.8:1. Score 6.3/10, moderate confidence.
Take-profit target: $33.15 (+46.6% upside). Target $33.15 (+46.6%), stop $21.42 (−5.6%), A.R:R 8.8:1. Stop-loss: $21.42.
Concentration risk — Product: lymphedema products (84.0%); Concentration risk — Supplier: single-source component suppliers; Below 200-MA, MA slope -2.4%/30d (confirmed downtrend).
Tactile Systems Technology, Inc trades at a P/E of 20.9 (forward 15.5). TrendMatrix value score: 8.1/10. Verdict: Hold.
10 analysts cover TCMD with a consensus score of 4.3/5. Average price target: $39.
What does Tactile Systems Technology, Inc do?Tactile Systems Technology (Tactile Medical) is a medical device company that develops at-home therapies for...
Tactile Systems Technology (Tactile Medical) is a medical device company that develops at-home therapies for underserved chronic conditions, primarily lymphedema and chronic venous insufficiency (Flexitouch Plus, Entre Plus, Nimbl) and chronic respiratory disease (AffloVest). The company generated $329.5 million in revenue in 2025, up 12% year over year, with lymphedema products contributing 84% of revenue and AffloVest 16%; net income was $19.1 million. Tactile sells lymphedema devices through a direct-to-patient and -provider model with in-network coverage from payers covering an estimated 2